Using mouse models of disease, we have shown that treatment with recombinant EGFL7 reduced VCAM-1 expression on ECs and led to reduction of T cell infiltration, resulting in significant GVHD improvement (92). The gene discussed is VCAM1; the disease is graft versus host disease.